Coya Therapeutics targets the critical progenitor of the inflammatory pathway – namely Treg dysfunction, regardless of abnormal, individual downstream pathways
Our pipeline focuses on chronic disease conditions, which are driven by regulatory T cell dysfunction and deficiencies. These conditions are ideally suited for our monthly maintenance regulatory T cell therapy
|Development Program||Product Candidate||Indication||Delivery Route||Pre-clinical||Phase I||Phase 2||Phase 3|
|Treg Cell Therapy||ALS 001||Amyotrophic Lateral Sclerosis||Intravenous||
|FTD 080||Frontotemporal Dementia||Intravenous||
|Treg Exosome Therapy||EXO 001||Amyotrophic Lateral Sclerosis||Undisclosed||
|EXO O50||Frontotemporal Dementia||Undisclosed||
* To date, work has been funded by private grants and foundational capital
ALS001: Phase 1 Study Results (n=3)*
- Treg percentage and suppressive function increased during infusions
- Enhanced Treg suppressive function correlated with slowing of functional decline
- MIPs (Respiratory Function) stabilized during infusions
INFUSIONS WERE FOUND TO BE SAFE
- No infusion-related adverse events were observed
- No clinically significant changes in laboratory findings
- No electrocardiogram findings were observed
- All patients noted increases in the frequency, intensity, and distribution of fasciculations during each round of infusions
Ongoing Phase 2a trial with data release scheduled for summer 2021
- Leverage monthly maintenance infusion of Tregs
- Determine the optimal dose and schedule of Treg infusion to increase the durability of response in patients with ALS
*Thonhoff J, et.al. Expanded autologous regulatory T-lymphocyte infusions in ALS. Neurol Neuroimmunol Neuroinflamm 2018 May
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative disease that attacks motor neurons in the brain and spinal cord. This results in the deterioration of muscle, loss of movement and eventual paralysis. There are an estimated 30,000 people living with ALS in the United States at any given time. Every 90 minutes, someone is diagnosed with ALS. About 90% of all ALS cases are sporadic with no known history of the disease in a family. The remaining 10% of cases are known as familial ALS.
Frontotemporal Dementia (FTD)
Frontotemporal dementia is an umbrella term for a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior and language.
In frontotemporal dementia, portions of these lobes shrink (atrophy). Signs and symptoms vary, depending on which part of the brain is affected. Some people with frontotemporal dementia have dramatic changes in their personality and become socially inappropriate, impulsive or emotionally indifferent, while others lose the ability to use language properly.
Frontotemporal dementia is often misdiagnosed as a psychiatric problem or as Alzheimer's disease. But frontotemporal dementia tends to occur at a younger age than does Alzheimer's disease. Frontotemporal dementia often begins between the ages of 40 and 65.
Autoimmune / Inflammatory Conditions
One of the functions of the immune system is to protect the body by responding to invading microorganisms, such as viruses or bacteria, by producing antibodies or sensitized lymphocytes (types of white blood cells). Under normal conditions, an immune response cannot be triggered against the cells of one's own body. In some cases, however, immune cells make a mistake and attack the very cells that they are meant to protect. This can lead to a variety of autoimmune diseases. They encompass a broad category of related diseases in which the person's immune system attacks his or her own tissue.
Dementia is not a single disease; it’s an overall term — like heart disease — that covers a wide range of specific medical conditions, including Alzheimer’s disease. Disorders grouped under the general term “dementia” are caused by abnormal brain changes. These changes trigger a decline in cognitive function, severe enough to impair daily life and independent function. They also affect behavior, feelings and relationships.
Parkinson's disease (PD) is a neurodegenerative disorder that affects predominantly dopamine-producing (“dopaminergic”) neurons in a brain region called the substantia nigra.
Symptoms generally develop slowly over years. The progression of symptoms varies from one person to another due to the diversity of the disease.
Alzheimers is a progressive neurodegenerative disease that causes widespread damage within the brain. This disease targets functioning neurons and disrupts their connections.
Without complete neural networks, information is unable to be transmitted properly throughout the brain.